Impact of the COVID-19 crisis on imaging in oncological trials.

Deroose, Christophe M;Lecouvet, Frédéric;Collette, Laurence;Oprea-Lager, Daniela E;deSouza, Nandita M;et.al.
(2020) European Journal of Nuclear Medicine and Molecular Imaging — Vol. 47, n° 9, p. 2054-2058 (2020)

Files

Deroose-2020-ImpactoftheCOVID-19.pdf
  • Open Access
  • Adobe PDF
  • 252.85 KB
Download

Details

Authors
Show more
Abstract
(en) The unprecedented demand for hospital services during the SARS-CoV-2 (COVID-19) pandemic has dramatically reduced the capability for dealing with non-acute health needs, including cancer care. To alleviate burden on health care systems, including imaging and laboratory services, curtailment of non-COVID-19-related research activity has been necessary. Measures that reduce hospital visits have been adopted to limit risk of infection and death, which is critical in a cancer population whose age and immunocompromised status increases their risk. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Deroose, C. M., Lecouvet, F., Collette, L., Oprea-Lager, D. E., Kunz, W. G., Bidaut, L., Verhoeff, J. J. C., Caramella, C., Lopci, E., Tombal, B., de Geus-Oei, L.-F., Fournier, L., Smits, M., & deSouza, N. M. (2020). Impact of the COVID-19 crisis on imaging in oncological trials. European Journal of Nuclear Medicine and Molecular Imaging, 47(9), 2054-2058. https://doi.org/10.1007/s00259-020-04910-y (Original work published 2020)